How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

801 results for

Lidocaine Patch

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

641. Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.

receptor blockers, membrane stabilizing agents (lidocaine mesylates, flecainide) or topical coanalgesics (capsaicin cream, lidocaine patch). Previous use of pregabalin or gabapentin. Preexisting pain at the site where the surgical incision will be made. Presence of a coexisting chronic pain syndrome. A creatinine clearance of less than 60 mL/min. A previous ipsilateral thoracotomy. A recent history of alcohol and/or drug abuse. A known allergy to local anesthetics or hydromorphone. The inability

2009 Clinical Trials

642. Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

. Information provided by (Responsible Party): ZARS Pharma Inc. Study Details Study Description Go to Brief Summary: The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome. Condition or disease Intervention/treatment Phase Carpal Tunnel Syndrome Drug: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch Phase 2 Detailed Description: ZARS Pharma, Inc. has developed Synera® (lidocaine 70 mg (...) and tetracaine 70 mg topical patch), a drug delivery patch that utilizes controlled heat to enhance the delivery of a local anesthetic formulation consisting of a eutectic mixture of lidocaine and tetracaine. Synera was approved by the Food and Drug Administration (FDA) on June 23, 2005 and is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodesiccation, and shave biopsy of skin lesions

2009 Clinical Trials

643. Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

neuropathic pain medications agents such as carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch, capsaicin cream, etc., or any other treatments specifically for prevention or treatment of neuropathy Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient Any of the following: Pregnant women Nursing women Women of childbearing potential (per physician judgment

2009 Clinical Trials

644. Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers

Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00889642

2009 Clinical Trials

645. Evaluate the Depth and Duration of Anesthesia

of the study is to determine the depth (mm) of anesthesia provided by the Synera topical patch (using sensory depth and pain depth evaluations), and to determine the duration (minutes) of anesthesia provided by the Synera topical patch (using dermal sensory testing and thermal sensory testing evaluations), compared with a matching heated placebo patch. Condition or disease Intervention/treatment Phase Pain Drug: Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine) Drug: Placebo Patch Phase 4 Study (...) Actual Primary Completion Date : April 2007 Actual Study Completion Date : April 2007 Arms and Interventions Go to Arm Intervention/treatment Experimental: Synera Drug: Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine) 30 minute applicable on antecubital fossa Placebo Comparator: Placebo Drug: Placebo Patch placebo Outcome Measures Go to Primary Outcome Measures : Sensory and pain depth measurements [ Time Frame: 0, 30, 60, 90, 120 and 150 minutes ] Dermal and thermal sensory testing

2009 Clinical Trials

646. A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers

(all concentrations), NGX-1998 (10% w/w) and CTL-V (0%) applied at each site application will be sufficient to evenly wet the surface. The top or bottom section of each application site will be pre-treated with lidocaine 2.5% / prilocaine 2.5% topical anesthetic cream. These sections are also the sections where the skin punch biopsies will be taken. The biopsy will be obtained from these sections as it is anticipated that subsequent clinical trials in patients will use pre-treatment with a topical (...) , including beta adrenergic blockers, alpha adrenergic blockers, anticonvulsant drugs, antidepressant drugs or opioids within 30 days prior to the Application Visit (Day 0). Current use of any class III anti-arrhythmic drugs (eg, amiodarone, bretylium, sotalol, dofetilide). Use of any topically-applied product, including prescription or over the-counter (OTC) analgesic creams/lotions/patches, non steroidal anti-inflammatory drugs, counterirritants, local anesthetics, steroids or capsaicin on the thighs

2009 Clinical Trials

647. Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee

Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine (...) Type : Interventional (Clinical Trial) Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Pain From Osteoarthritis of the Knee Study Start Date : June 2004 Actual Primary Completion Date : November 2004 Actual Study Completion Date : November 2004 Resource links provided by the National Library

2009 Clinical Trials

648. Topical Lidocaine Patch in Low Back Pain

Topical Lidocaine Patch in Low Back Pain Topical Lidocaine Patch in Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical Lidocaine Patch in Low Back Pain The safety and scientific validity (...) ) Primary Purpose: Treatment Official Title: Open-Label Study Assessing the Efficacy of Topical Lidocaine Patch in Treatment of Low Back Pain Study Start Date : March 2002 Actual Primary Completion Date : October 2002 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Lidoderm® Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h

2009 Clinical Trials

649. Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

Information provided by: Endo Pharmaceuticals Study Details Study Description Go to Brief Summary: Patients with moderate to severe chronic Low Back Pain (LBP) despite current analgesic treatment participated in a Phase IV clinical trial to evaluate the analgesic efficacy of the lidocaine patch 5% compared to placebo in treating moderate to severe chronic LBP. Condition or disease Intervention/treatment Phase Chronic Low Back Pain Drug: Lidoderm® Phase 4 Study Design Go to Layout table for study (...) by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1- Lidoderm® Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain Drug: Lidoderm® Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h. Other Name: Lidocaine

2009 Clinical Trials

650. Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00904462 Recruitment Status : Completed First Posted : May 19, 2009 Last Update Posted : February 10, 2010

2009 Clinical Trials

651. Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine (...) Pharmaceuticals Information provided by: Endo Pharmaceuticals Study Details Study Description Go to Brief Summary: Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chronic axial LBP with and without radiation. Condition or disease Intervention/treatment Phase Chronic

2009 Clinical Trials

652. A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions The safety and scientific validity of this study is the responsibility

2009 Clinical Trials

653. A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain

A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00904111 Recruitment Status : Completed First

2009 Clinical Trials

654. A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

Experimental: (1) Lidoderm (1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Drug: Lidoderm Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Other Name: Lidocaine patach 5% Outcome Measures Go (...) ) [ Time Frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14) ] QoL: Patient Global Assessment of Patch Satisfaction [ Time Frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14) ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff

2009 Clinical Trials

655. Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidoderm® (...) (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00903851 Recruitment Status : Completed First Posted : May 19, 2009 Last Update Posted : February 15, 2010 Sponsor: Endo Pharmaceuticals Information provided by: Endo Pharmaceuticals Study Details

2009 Clinical Trials

656. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia. Full Text available with Trip Pro

Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia. Topical lidocaine patch is effective in the treatment of post-herpetic neuralgia (PHN), but not suited for paroxysmal pain because of the long latency of analgesia. Here, we examined the efficacy of 8% lidocaine pump spray (Xylocaine pump spray, XPS) for PHN.Twenty-four patients with PHN were recruited into a randomized, double-blind, placebo-controlled, crossover study (study 1), and 100 patients

2009 Pain medicine (Malden, Mass.) Controlled trial quality: uncertain

657. Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. Full Text available with Trip Pro

Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. Reduced postoperative pain is one of the many factors that have driven the growing emphasis on the role of laparoscopic surgery for surgical management. Several studies have documented the advantages of the laparoscopic repair of ventral hernias compared to the open ventral herniorraphy. However, the laparoscopic approach may be associated with more postoperative pain initially (...) . In this preliminary study, we present data from our early experience with the use of a lidocaine patch for pain control in the immediate postoperative period following laparoscopic ventral hernia repair (LVH).Thirty consecutive patients underwent laparoscopic ventral herniorraphy (LVH) and were selected randomly and placed into one of two groups. In one group, we placed a lidocaine patch (LP) (Lidoderm, Endo Pharmaceuticals, Inc., Chadds Ford, PA) on the anterior abdominal wall corresponding to the placement site

2009 International journal of surgery (London, England) Controlled trial quality: uncertain

658. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Full Text available with Trip Pro

Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. We compared the lidocaine/tetracaine patch [Synera (USA), Rapydan (Europe)], a novel heat-aided patch using a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg, with a eutectic mixture of lidocaine 25 mg ml(-1) and prilocaine 25 mg ml(-1) (EMLA Cream). The agents were administered at different time periods for local topical anaesthesia before (...) a vascular access procedure.In this double-blind, paired study, 82 adult volunteers were randomized to receive the lidocaine/tetracaine patch on one anticubital surface and lidocaine/prilocaine cream on the other concurrently for 10, 20, 30, or 60 min before a vascular access procedure. Subjects rated pain intensity using a 100 mm visual analogue scale (VAS). Skin reactions and adverse events were also evaluated.Median VAS scores were significantly lower for the lidocaine/tetracaine patch than

2009 British Journal of Anaesthesia Controlled trial quality: uncertain

659. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Full Text available with Trip Pro

Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Current therapies often have limited efficacy and untenable side effects when used to treat persistent incisional pain following cancer-related surgery. Lidocaine patches reduce neuropathic pain from herpes zoster but their benefits for persistent cancer-related postsurgical incisional pain remain unclear.Multicenter, double-blind, randomized (...) , two-period crossover trial.Twenty-eight cancer patients with postsurgical incisional pain were randomly assigned to receive either lidocaine patches followed by placebo patches or the reverse. Each study period lasted 4 weeks. Patches were applied daily upon waking and left in place for a maximum of 18 h. The primary outcome measure, an 11-point pain intensity rating scale, was administered weekly. Secondary outcomes were administered weekly (Brief Pain Inventory-Short Form(BPI-SF), Subject Global

2009 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Controlled trial quality: predicted high

660. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. (Abstract)

A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Myofascial pain syndrome (MPS), a regional pain condition caused by trigger points in muscle or muscle fascia, produces muscle pain, tenderness, and disability. The gold standard of treatment for MPS-infiltration of trigger points with anesthetic-may provoke discomfort (...) to the patients and require medical intervention.This study was designed to compare the effects of a topical lidocaine patch, a placebo patch, and injection of anesthetic (infiltration) for the symptoms of MPS in terms of pain, disability, and local tissue hypersensitivity, and to determine the acceptability of the lidocaine patch to the patients.Patients were randomly allocated to receive 1 of 3 treatments: a lidocaine patch applied to the trigger point for 4 days (replacement every 12 hours; total daily

2009 Clinical therapeutics Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>